Magadh Chronicle

Desmoid Tumors Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

 Breaking News
  • No posts were found

Desmoid Tumors Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight

January 18
18:17 2023
Desmoid Tumors Clinical Trials | A Drug Pipeline Analysis Report 2023 | DelveInsight
Desmoid Tumors Pipeline Insights
United States, Nevada, Las Vegas, DelveInsight’s ‘Desmoid Tumors Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline Desmoid Tumors therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Desmoid Tumors pipeline domain.

United States, Nevada, Las Vegas, DelveInsight’s Desmoid Tumors Pipeline Insight 2023 report provides comprehensive global coverage of available, marketed, and pipeline Desmoid Tumors therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Desmoid Tumors pipeline domain.

Key Takeaways from the Desmoid Tumors Pipeline Report

  • Over 12+ Desmoid Tumors pipeline therapies are in various stages of development, and their anticipated acceptance in the Desmoid Tumors market would significantly increase market revenue. 
  • Leading Desmoid Tumors companies developing novel drug candidates to improve the Desmoid Tumors treatment landscape include SpringWorks Therapeutics, Iterion Therapeutics, and others.
  • Promising Desmoid Tumors pipeline therapies in various stages of development include Nirogacestat, Tegavivint, and others.

Desmoid Tumors Overview

Desmoid tumors is an abnormal growth that arises from connective tissue. “Desmoid”” comes from the Greek word desmos, which means tendon or band-like. These are also known as aggressive fibromatosis or desmoid-type fibromatosis. Desmoid tumors often appear as infiltrative, usually well-differentiated, firm overgrowths of fibrous tissue, and they are locally aggressive. Desmoid tumors can occur in any part of body but most often occur in the abdomen, arms and legs. These are generally not considered cancerous (malignant) because they do not spread to other body parts (metastasize); however, they can aggressively invade the surrounding tissue and can be very difficult to remove surgically. Desmoid tumors occur frequently in people with an inherited form of colon cancer called familial adenomatous polyposis.

Desmoid Tumors Pipeline Analysis: Drug Profile

Nirogacestat: SpringWorks Therapeutics

Nirogacestat is an oral, selective, small molecule, gamma-secretase inhibitor. It is currently in Phase 3 clinical development for patients with desmoid tumors. The U.S. FDA has granted nirogacestat Orphan Drug Designation for the treatment of desmoid tumors and Fast Track and Breakthrough Therapy Designations for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis.

Discover more about the emerging Desmoid Tumors drugs @ Desmoid Tumors Treatment Drugs

Desmoid Tumors Key Companies

  • SpringWorks Therapeutics
  • Iterion Therapeutics

Desmoid Tumors Pipeline Therapies

  • Nirogacestat
  • Tegavivint

Desmoid Tumors Pipeline Therapeutics Assessment

  • By development stage
  • By product type
  • By route of administration
  • By molecule type
  • By MOA type 

Scope of the Desmoid Tumors Pipeline Report 

  • Coverage: Global 
  • Key Desmoid Tumors Companies: SpringWorks Therapeutics, Iterion Therapeutics, and others
  • Key Desmoid Tumors Pipeline Therapies: Nirogacestat, Tegavivint, and others

Find out more about the Desmoid Tumors treatment options in development @ Desmoid Tumors Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Request for a sample report to know more about the leading companies in the Desmoid Tumors Pipeline Segment.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/